Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05905887 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Aug 31, 2026 to Aug 31, 2027
    • Study completion date: Dec 31, 2026 to Dec 31, 2027
    • Site details revised
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 15, 2023 to Sep 6, 2023
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy and safety of rivoceranib and paclitaxel combination therapy in patients with P-glycoprotein overexpressing GIST who failed standard treatment with imatinib, sunitinib, and regorafenib.
Trial Details
NCT Number NCT05905887
Lead Sponsor Asan Medical Center
Conditions
(from sponsor)		 Gastrointestinal Stromal Tumors
Related terms Gastrointestinal Stromal Tumors
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov